NCT05630274View on ClinicalTrials.gov

A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

April 16, 2019

Primary Completion Date

June 21, 2019

Study Completion Date

June 21, 2019

Conditions

Healthy

Interventions

DRUG

Selpercatinib

Administered orally

DRUG

Moxifloxacin

Administered orally

DRUG

Placebo

Administered orally.

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Collaborators (1)

Loxo Oncology, Inc.

All Listed Sponsors

collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT05630274 - A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants | Biotech Hunter | Biotech Hunter